Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD)

PHASE4CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Renal Insufficiency, Chronic
Interventions
DRUG

Rilonacept

12 weeks of treatment with rilonacept (subcutaneous injection with a loading dose of 320 mg, followed by 160 mg/wk)

DRUG

Placebo

Twelve weeks of treatment with placebo (subcutaneous injection of normal saline with a loading dose of 320 mg, followed by 160 mg/wk)

Trial Locations (2)

37232

Vanderbilt University Medical Center, Nashville

80045

University of Colorado Clinical and Translational Research Center (CTRC) Outpatient Clinic, Aurora

All Listed Sponsors
lead

University of Colorado, Denver

OTHER

NCT01663103 - Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD) | Biotech Hunter | Biotech Hunter